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Objective: Pigment epithelium-derived factor is known to be an inhibitor of angio-
genesis. We hypothesized that in vivo gene transfer of pigment epithelium-derived
factor may inhibit tumor angiogenesis and growth in syngeneic models of thoracic
malignancies.
Methods: An adenovirus vector encoding the human pigment epithelium-derived
factor cDNA (AdPEDF) was used to transduce human lung cancer cells in vitro.
Transgene expression was assessed using Western analysis. Three different murine
flank tumors (2 lung, 1 colon) were then established in syngeneic mice and treated
intratumorally with phosphate-buffered saline, AdPEDF, or an empty vector (Ad-
Null). Endpoints measured included transgene expression, tumor size, and animal
survival, as well as microvessel density within the tumor. Additionally, a murine
pulmonary metastasis model was established by intravenous injection of a syngeneic
colon adenocarcinoma cell line expressing a marker gene (-galactosidase). One
day later, treatment (phosphate-buffered saline, AdNull, or AdPEDF) was admin-
istered intrapleurally. Tumor burden (gross and histologic inspection, lung weight,
and -galactosidase expression) was then evaluated 13 days after vector dosing, and
survival was recorded.
Results: AdPEDF-derived expression of pigment epithelium-derived factor was
demonstrated in vitro and in vivo. In syngeneic murine lung cancer flank tumors,
intratumoral administration of AdPEDF significantly inhibited tumor growth (P 
.01), prolonged mouse survival (P  .01), and decreased microvessel density
(P  .01) compared with control groups. In the pulmonary metastasis model,
AdPEDF-treated mice exhibited significantly reduced lung lesions, lung weight
(P  .0005), -galactosidase expression (P  .05), and animal survival was
prolonged (P  .05).
Conclusion: Gene transfer of pigment epithelium-derived factor suppresses tumor
vascularization and growth, while prolonging survival in syngeneic murine models
of thoracic malignancies.
Angiogenesis is known to be a series of linked and sequential stepsthat ultimately leads to the development of a neovascular bloodsupply to a tumor mass and is crucial for the continuous growthof tumors and the development of metastases.1-3 Tumor massesless than 0.5 mm in diameter receive necessary nutrients andoxygen through diffusion; however, any growth beyond 0.5 mm
requires neovascularization.2 Therefore, expansion of tumors beyond a microscopic
size is dependent on two cellular components growing in tandem: tumor cells and
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microvascular endothelial cells.3 To accommodate their
continued proliferation, tumor cells secrete proangiogenic
factors (eg, vascular endothelial growth factor), which in-
duce endothelial cell proliferation, migration, and eventu-
ally capillary tube formation.1-3 Because angiogenesis is
essential for tumor growth and metastasis formation, efforts
to discover effective antiangiogenic compounds are warranted.
Pigment epithelium-derived factor (PEDF), a 50-kDa
protein first purified from the conditioned media of human
retinal pigment epithelial cells,4 has neuroprotective activ-
ities.5-7 In addition, PEDF has recently been shown to be a
potent inhibitor of both choroidal and retinal angiogenesis
in animal models.8-12 A phase I clinical trial evaluating
intravitreal adenovirus (Ad)-mediated gene transfer of the
human PEDF cDNA in patients with age-related macular
degeneration has been proposed based on these data.13
Given this background, we hypothesized that PEDF may
exhibit antitumor properties, based on its ability to inhibit
angiogenesis. The objectives of this study are to determine
if (1) intratumoral administration of an Ad vector encoding
the human PEDF cDNA (AdPEDF) will result in PEDF
expression and inhibit the growth of syngeneic murine lung
cancers in an established flank tumor model; (2) the antitu-
mor effect of AdPEDF will be preserved in 3 different
strains of immunocompetent mice bearing 3 different estab-
lished syngeneic tumors; (3) intrapleural delivery of
AdPEDF will result in significantly reduced tumor burden
and prolonged survival in an orthotopic murine pulmonary
metastasis model; (4) tumors injected with AdPEDF will
exhibit evidence of angiogenesis inhibition.
Methods
Mice
Six- to 8-week-old male wild-type BALB/c (H-2d), wild-type
C57BL/6 (H-2b), and wild-type DBA/2 (H-2d) mice were obtained
from the Jackson (Bar Harbor, Maine) and/or Taconic (German-
town, NY) laboratories. Animals were housed under specific
pathogen-free conditions and treated according to National Insti-
tutes of Health Guidelines, and all animal procedures were ap-
proved by the Institutional Animal Care and Use Committee.
Cell Culture
CT26 is an undifferentiated colon adenocarcinoma (H-2d, synge-
neic to BALB/c mice) originally derived by intrarectal injections
of N-nitro-N-methylurethane in a female BALB/c mouse.
CT26.CL25 was derived from CT26 cells modified to express the
Escherichia coli -galactosidase (-gal) gene (both cell lines
kindly provided by N.P. Restifo, National Cancer Institute, Be-
thesda, Md). Lewis lung carcinoma (LLC; H-2b, syngeneic to
C57BL/6), KLN205 (H-2d, a murine lung squamous cell carci-
noma syngeneic to DBA/2 mice), and A549 cells, a human lung
carcinoma, were obtained from the American Type Culture Col-
lection (ATCC; Manassas, Va). CT26 was maintained in complete
(10% fetal bovine serum, 100 g/mL streptomycin sulfate and 100
U/mL penicillin G) RPMI 1640. CT26.CL25 was maintained in
similar medium plus 400 g/mL G418 (Invitrogen Corporation,
Carlsbad, Calif). LLC and A549 cells were maintained in complete
Dulbecco’s modified Eagle’s medium (DMEM). KLN205 cells
were maintained in complete minimum essential medium with the
addition of 0.1 mM nonessential amino acids (Invitrogen).
Adenovirus Vectors
All Ad vectors used in this study are replication-deficient, E1-,
E3-, serotype 5 vectors, and were propagated in human embryonic
kidney (293) cells (ATCC), purified by 2 rounds of cesium chlo-
ride density gradient ultracentrifugations, then dialyzed as previ-
ously described.14,15 Viral particle concentration was determined
by ultraviolet absorbance at 260 nm.16 AdPEDF contains an ex-
pression cassette with the cytomegalovirus early/immediate gene
promotor/enhancer driving the human PEDF cDNA (GenVec Inc,
Gaithersburg, Md).9 AdNull is a similar vector but contains no
transgene.17
Western Analysis
To confirm production of PEDF, A549 cells were transduced with
AdNull or AdPEDF at an MOI (multiplicity of infection) of 104
particles per cell, then plated at a concentration of 5  105
cells/100 L of serum-free DMEM into each well of a 96-well
plate (Becton Dickinson, Franklin Lakes, NJ). Cells “transduced”
with phosphate-buffered saline (PBS) served as further controls
(sham transduced). After 48 hours of incubation at 37°C, the
overlying supernatant was collected and subjected to Western
analysis. Briefly, samples were resolved using 10% sodium dode-
cyl sulfate polyacrylamide gel electrophoresis, then transferred to
a nitrocellulose membrane (Bio-Rad, Hercules, Calif) for Western
analysis using a monoclonal rabbit anti-human PEDF antibody
(Chemicon International, Temula, Calif) as the primary antibody
and a donkey anti-rabbit immunoglobulin G (IgG; Jackson Immu-
noResearch Laboratories, West Grove, Pa) as the secondary anti-
body. Immunoreactivity was detected by chemiluminescence (Am-
ersham Pharmacia Biotech, Piscataway, NJ). Recombinant human
PEDF peptide (residues 196 to 347, 46 kDa) was used as a positive
control (100 ng; Chemicon International).
Subcutaneous Flank Tumor Model and Vector
Administration
Tumor cells (2 105 CT26, 5 105 LLC, or 2.5 105 KLN205)
were injected subcutaneously into the flanks of syngeneic mice.
When the tumors reached approximately 30 mm2 (day 7 to 12),
PBS, AdNull (5  1010 particles/100 L PBS), or AdPEDF (5 
1010 particles/100 L PBS) was injected intratumorally. Because
some tumors grew into oblong nodules, as opposed to spheres, the
size of the flank tumor was assessed in situ every 2 to 3 days by
measuring the largest perpendicular diameters using microcalipers,
and recorded as average tumor area (mm2). When the animals
appeared moribund or the tumor growth exceeded 15 mm in
largest diameter, the mice were sacrificed, and this time point was
defined as death for survival analysis.
To confirm PEDF production in vivo, established CT26 flank
tumors were injected with PBS, AdNull, or AdPEDF as described
above. Three days after intratumoral vector administration, flank
tumors were harvested, homogenized in lysis buffer, centrifuged,
and concentrated using Microcon centrifugal filter units (Millipore,
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Bedford, Mass) to eliminate proteins larger than 100 kDa and
smaller than 10 kDa. After concentration, the filtrate was subjected
to Western analysis as described above.
Pulmonary Metastasis Model and Intrapleural Vector
Administration
A murine pulmonary metastasis model was established by inject-
ing 3 105 CT26.CL25 cells suspended in 100 L of PBS into the
right internal jugular vein of BALB/c mice. Vectors were then
administered into the right pleural cavity 1 day after the intrave-
nous tumor bolus.18 Intrapleural administration of dilute (1:5 in
PBS) methylene blue dye (1 mL) was initially performed to
evaluate whether interpleural communication exists in BALB/c
mice. To perform intrapleural gene delivery, mice were anesthe-
tized via intraperitoneal injection with a cocktail of ketamine (100
mg/kg) and xylazine (10 mg/kg). The trachea was cannulated with
a 22-gauge angiocatheter (Becton Dickinson) and mechanical ven-
tilation was achieved with a small animal ventilator (Harvard
Apparatus, Holliston, Mass). Next, a 5-mm right anterolateral
thoracotomy was performed at approximately the level of the fifth
intercostal space. Either PBS, AdNull (1010 particles/100 L
PBS), or AdPEDF (1010 particles/100 L PBS) was injected into
the hemithorax, followed by a single simple absorbable suture to
close the interspace. The skin was closed with absorbable 4-0
suture. Once spontaneous respirations were noted, the intratracheal
angiocatheter was removed, mechanical ventilation discontinued,
and the pretracheal incision sutured. Tumor burden was then
quantified 13 days after vector dosing and animal survival was
recorded.
Quantification of Tumor Burden in the Lungs
To quantify lung tumor burden 3 different endpoints were exam-
ined: lung weight, gross and microscopic inspection, as well as
lung -gal expression. Thirteen days after vector dosing, animals
were sacrificed at designated time points, and the lungs were
harvested en bloc and dissected free from the thymus, heart, and
other mediastinal structures. For each mouse, the right and left
lungs were isolated and each immediately weighed (wet weight).
Next, lungs were homogenized in lysis buffer, and -gal gene
expression was measured in a luminometer (Monolight 3010C,
PharMingen, San Diego, Calif) using the Galacto-Light Plus kit
(Tropix, Bedford, Mass). In addition, the total protein was quan-
tified for each lung using the Bio-Rad protein assay kit (Bio-Rad
Laboratories, Hercules, Calif). -gal expression in the lung is
reported as total activity in relative light units (RLU) normalized to
total protein.
Lungs from additional animals were stained with India ink and
subjected to gross inspection.19 Briefly, the animals were sacri-
ficed, the trachea was cannulated in situ with a 22-gauge angio-
catheter, and 1 mL of 15% India ink (Sanford, Bellwood, Ill)
solution was slowly infused into the lungs. Next, the intrathoracic
organs were harvested en bloc and placed in Fekete’s solution
(70% ethanol, 10% formaldehyde, 5% acetic acid) at 4°C over-
night. Gross photographs were taken the next day. Finally, lungs
were fixed and stained for histologic evaluation. To accomplish
this, the animals were sacrificed, the trachea was cannulated in situ
with a 22-gauge angiocatheter, and 1 mL of 4% paraformaldehyde
(PFA) was slowly infused into the lungs. Next, the intrathoracic
organs were harvested en bloc and placed in a 4% PFA at 4°C
overnight. The lungs were then embedded in paraffin, and butter-
fly-shaped sections (5 m) were cut and stained with hematoxylin-
eosin, followed by evaluation using photomicroscopy.
Evaluation of Microvessel Density
Six days after injection of LLC flank tumors with PBS, AdNull, or
AdPEDF, tumors were harvested, embedded in optimum cutting
Figure 1. AdPEDF-induced expression of PEDF protein in vitro
and in vivo. (A) In vitro A549 cells were transduced (MOI 104
particles/cell) with AdNull or AdPEDF. Sham transduced cells
(PBS) served as further controls. After 48 hours of incubation, the
media was collected and Western analysis performed for the
presence of PEDF protein. Lane 1, 100 ng of PEDF protein (
control, 46 kDa); lane 2, sham-transduced cells; lane 3, AdNull-
transduced cells; and lane 4, AdPEDF-transduced cells. (B) In vivo
established CT26 flank tumors were injected at day 7 with 5 
1010 particles of AdNull or AdPEDF. Sham injected tumors (PBS)
served as further controls. Three days following vector injection,
flank tumors were excised, homogenized, pooled, concentrated,
and Western blot analysis performed for the presence of PEDF
protein. Lane 1, sham-injected tumors; lane 2, AdNull-injected
tumors; lane 3, AdPEDF-injected tumors; lane 4, 100 ng of PEDF
protein ( control). The band at 60 kDa in lanes 1 to 3 is
nonspecific.
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temperature compound (Sakura Finetek, Torrance, Calif), snap-
frozen in a 2-methylbutane/dry ice bath, and 8 m frozen sections
were cut. Immunohistochemical staining for endothelial cells was
then performed to determine microvessel density. Briefly, frozen
sections were dried for 90 minutes, blocked with normal rabbit
serum (Vector Laboratories, Burlingame, Calif) for 30 minutes,
washed with PBS, and incubated with rat anti-mouse CD34 mono-
clonal antibody (Pharmingen, San Diego, Calif) for 3 hours. Slides
were then washed with PBS, incubated with biotinylated rabbit
anti-rat IgG antibody (Vector Laboratories) for 60 minutes,
Figure 2. Intratumoral administration of AdPEDF inhibits the growth of established murine tumors and prolongs
mouse survival in vivo. Subcutaneous flank tumors (CT26, LLC, or KLN 205) were established in syngeneic mice,
followed by intratumoral injection of either PBS, AdNull (5  1010 particles/100 L PBS), or AdPEDF (5  1010
particles/100 L PBS). Tumor size (area) was measured at 2- to 3-day intervals and survival was recorded. Animals
were sacrificed when the largest tumor diameter reached 15 mm. (A, B) CT26 tumors in BALB/c mice (PBS group
n 8, AdNull and AdPEDF groups n 7). (C, D) LLC tumors in C57BL/6 mice (all groups n 6). (E, F) KLN205 tumors
in DBA/2 mice (PBS and AdNull groups n  4, AdPEDF group n  5). For panels A, C, and E, the data are reported
as mean  SEM. Arrows indicate day of vector administration.
Mahtabifard et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 1 31
G
TS
washed again, and incubated with an avidin-horseradish peroxi-
dase complex (Ventana Medical Systems, Tucson, Ariz) for 8
minutes. Following a final wash, slides were exposed to 3'3'
diaminobenzidine chromogen substrate for 8 minutes, washed,
stained with hematoxylin for background staining, rehydrated, and
mounted for microscopy. To perform a quantitative assessment of
microvessel density, 2 different, blinded observers counted the
number of vessels per high power field (HPF; 40). This was
performed for 6 HPFs per treatment group. Data are reported as the
mean (standard error) number of vessels counted per HPF for the
3 treatment groups.
Statistical Analysis
All data are reported as mean  standard error. Statistical signif-
icance between means was determined using the unpaired, two-
tailed Student t test. Survival evaluation was carried out using
Kaplan-Meier analysis, with the P value determined by log-rank
analysis (SPSS).
Results
AdPEDF Induces PEDF Expression In Vitro and In
Vivo
To determine whether AdPEDF induces PEDF expression
in vitro, A549 cells were transduced with AdNull or
AdPEDF. Sham transduced cells served as further controls.
After 48 hours of incubation, PEDF protein expression was
detected only in the supernatant overlying cells transduced
with AdPEDF compared with controls (Figure 1, A).
To confirm the function of AdPEDF in vivo, established
day 7 CT26 flank tumors were injected with PBS, AdNull,
or AdPEDF. Three days following intratumoral vector ad-
ministration, Western analysis performed on the tumor ho-
mogenates demonstrated the presence of PEDF only in
tumors injected with AdPEDF compared with controls (Fig-
ure 1, B).
Figure 3. Pulmonary metastasis model. CT26.CL25 cells (3 105 in 100 L PBS) were injected via the right internal
jugular vein into BALB/c mice. At defined time points after tumor initiation, the lungs were harvested, weighed, and
-gal gene expression was quantified as described in Methods. -gal expression in the lungs is reported as total
activity in RLU normalized to total protein. The data represent mean standard error (all time points n 5, except
day 12 group n  4 mice per group). (A) Left lung weight. (B) Right lung weight. (C) Left lung -gal expression. (D)
Right lung -gal expression. *Undetectable level of -gal expression.
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Intratumoral Administration of AdPEDF Inhibits the
Growth of Established Flank Tumors and Prolongs
Mouse Survival
The ability of PEDF gene transfer to inhibit tumor growth in
vivo was first evaluated by injecting established subcutane-
ous flank tumors with AdPEDF and following their growth
over time. Experiments were performed in three syngeneic
tumors (2 lung and 1 colon) in three different but corre-
sponding syngeneic strains of mice. The administration of
AdPEDF significantly inhibited the growth of CT26 tumors
when compared with either AdNull or PBS (Figure 2, A,
AdPEDF versus AdNull, P .01). In addition, intratumoral
administration of AdPEDF resulted in prolonged survival of
animals (Figure 2, B, AdPEDF versus AdNull, P  .005).
To determine if the antitumor effect of AdPEDF was
specific to CT26 tumors in BALB/c mice, LLC tumors in
C57BL/6 mice and KLN205 tumors in DBA/2 mice were
treated in a similar fashion. As in the CT26 model, signif-
icant inhibition of tumor growth by AdPEDF was observed
in both tumors/strains compared with the control groups
(Figure 2, C, P  .00005; Figure 2, E, P  .0001; AdPEDF
versus AdNull). Survival advantage was again demon-
strated in the AdPEDF groups compared with the PBS and
AdNull treated groups (Figure 2, D, P  .01; Figure 2, F,
P  .05; AdPEDF versus AdNull).
Intrapleural Delivery of AdPEDF Decreases Tumor
Burden and Prolongs Survival in a Murine Pulmonary
Metastasis Model
To enhance the ability to quantify tumor burden in the
lungs, pulmonary metastases were induced using a cell line
that expresses a marker gene. BALB/c mice were injected
intravenously with CT26.CL25 cells and lungs were har-
vested on subsequent days in the absence of any treatment.
At each time point, both wet lung weight and -gal gene
expression were used to quantify lung tumor burden. Fol-
lowing injection of tumor, but no therapy, both left and right
lung weights increased incrementally as a function of time
(Figures 3, A and B). Similarly, -gal gene expression
increased in a corresponding fashion (Figures 3, C and D).
Growth of pulmonary metastases was markedly sup-
pressed by intrapleural administration of 1010 particles of
AdPEDF (Figures 4, 5, and 6). Preliminary experiments
with administration of methylene blue dye into a single
Figure 4. Gross photographs demonstrating the effect of intrapleural AdPEDF administration on the growth of lung
metastases. One day after intravenous administration of 3  105 CT26.CL25 tumor cells, 1010 particles of AdPEDF,
AdNull, or PBS was injected into the right pleural space of BALB/c mice. Thirteen days after vector dosing, the
heart-lung complex was harvested en bloc and stained as described in “Methods.” Metastatic lung nodules
appear white on a background of black (from India ink infusion) normal parenchyma. (A) Control, naı¨ve lung. (B)
Intrapleural PBS. (C) Intrapleural AdNull. (D) Intrapleural AdPEDF.
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pleural cavity demonstrated dissemination of the dye
throughout both hemithoraces (not shown). Thirteen days
after vector treatment, control (PBS and AdNull) lungs
possessed numerous large, bilateral, and confluent pulmo-
nary nodules (Figures 4, B and C) in comparison to naı¨ve
(no tumor bolus) lungs (Figure 4, A). In distinct contrast,
lungs from mice that received intrapleural AdPEDF pos-
sessed a paucity of lung nodules bilaterally (Figure 4, D).
Histologic evaluation of lungs 13 days after treatment re-
vealed similar results (Figure 5). Lungs from mice injected
with intrapleural AdPEDF exhibited markedly less tumor
than those from control (PBS and AdNull) animals (Figures
5, B, C, and D). A heart-lung complex from a naı¨ve mouse
(no tumor bolus) is shown for comparison (Figure 5, A).
To further quantify tumor burden, lung weights and
-gal expression were recorded. Animals that received in-
trapleural AdPEDF had significantly decreased lung
weights compared with controls (Figures 6, A and B;
AdPEDF\ versus AdNull, left and right, P  .000005 and P
 .0005, respectively). When -gal gene expression in the
lungs was quantified, a similar pattern was observed. -gal
expression in the left and right lungs of mice receiving
intrapleural AdPEDF was markedly diminished when com-
pared with PBS and AdNull treated mice (Figures 6, C and
D; AdPEDF versus AdNull, left and right, P  .05 and P 
.01, respectively). AdPEDF treatment also prolonged the
survival of mice with pulmonary metastases, compared with
controls (Figure 7; AdPEDF versus AdNull, P  .05).
Intratumoral Administration of AdPEDF Diminishes
Tumor Microvessel Density
The ability of PEDF gene transfer to inhibit angiogenesis
was evaluated by immunohistochemical analysis of treated
flank tumors, with blinded quantification of microvessel
density. Blood vessels were significantly less dense in tu-
mors treated with AdPEDF, when compared with controls,
a finding that was corroborated by 2 different, blinded
observers (Figure 8; AdPEDF versus AdNull, P  .01). No
significant difference in vessel density was appreciated be-
tween tumors that received a sham injection (PBS) and
AdNull (Figure 8; PBS versus AdNull, P  .1).
Figure 5. Lung histology demonstrating the effect of intrapleural AdPEDF administration on the growth of lung
metastases. The experiment is similar to that described in Figure 4. Thirteen days after vector injection, the lungs
were harvested, fixed, cut, and stained with hematoxylin and eosin. (A) Control, naı¨ve lung. (B) Intrapleural PBS.
(C) Intrapleural AdNull. (D) Intrapleural AdPEDF.
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Pigment epithelium-derived factor was first purified from
the conditioned media of human retinal pigment epithelial
cells and was shown to induce neuronal differentiation of
cultured retinoblastoma cells.4 PEDF resembles in sequence
and structure members of the serine protease inhibitor (ser-
pin) family20 but lacks protease inhibitor activity itself.21
PEDF has been shown to have neuroprotective activity6 and
to protect photoreceptors from degeneration.7 Interestingly,
PEDF also inhibits endothelial cell migration and prolifer-
ation and has been shown to inhibit choroidal and retinal
neovascularization.8-12 PEDF has been used in gene therapy
using both an Ad vector and adeno-associated virus (AAV)
vector.9,11,12 Intravitreous and subretinal injections of either
recombinant PEDF or a viral vector (Ad or AAV) encoding
PEDF have resulted in increased expression of PEDF in the
eye and significantly reduced neovascularization in murine
models of choroidal and retinal neovascularization.9-12
Given the antiangiogenic properties of PEDF, this study
is based on the hypothesis that in vivo PEDF gene transfer
using an Ad vector may inhibit tumor growth. Consistent
with this hypothesis, the data demonstrate that Ad-mediated
transfer of the human PEDF cDNA to established murine
tumors inhibits tumor growth and prolongs animal survival;
this inhibition correlates with a decrease in tumor vascular-
ization. Furthermore, intrapleural administration of
AdPEDF results in suppression of growth of pulmonary
metastases and enhances host survival.
AdPEDF as an Antineoplastic Agent
Angiogenesis is a complex, multistep process that is essen-
tial for the growth of tumors and their metastasis.1-3 Be-
cause PEDF has been shown to be a potent inhibitor of
angiogenesis, its role as an antitumor agent is intuitive. In
this regard, the present study clearly demonstrates the anti-
neoplastic effect of PEDF in two separate, syngeneic mod-
els of thoracic malignancies. Lung cancer and metastatic
colon carcinoma to the lungs were chosen as models to
evaluate AdPEDF, given that these are common thoracic
malignancies where novel therapies are desirable.
Intrapleural gene delivery as a strategy to express pro-
teins in the pulmonary parenchyma is a novel approach that
Figure 6. Intrapleural administration of AdPEDF suppresses the growth of pulmonary metastases. The experiment
is similar to that described in Figure 4. Thirteen days after vector injection, lungs were harvested, separated,
weighed, and -gal expression was measured. -gal activity in the lung was expressed as RLU normalized to total
protein. The data represent mean  standard error (naı¨ve and PBS groups n  6, AdNull and AdPEDF groups n 
5 mice per group). (A) Left lung weight. (B) Right lung weight. (C) Left lung -gal expression. (D) Right lung -gal
expression. *Undetectable level of -gal expression.
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has only recently been described.18 As gene expression is
seen primarily in the periphery of the lung using this tech-
nique, penetration of the vector through the visceral pleura
represents the most likely mechanism. The observation that
instillation of AdPEDF into 1 pleural space results in tumor
suppression bilaterally is best explained by the communi-
cation between hemithoraces in the BALB/c mouse,18
which was readily demonstrable with methylene blue dye.
In this regard, intrapleural administration of AdPEDF for
pulmonary metastases in humans will likely require bilateral
dosing. In addition, the effect of the relatively large size of
the human pleural space (compared with the mouse) may
impact on the excellent results seen in this murine model.
Despite these potential limitations, intrapleural therapy for
metastatic lung disease is a novel strategy with potential
clinical application.18
An Ad vector was chosen as the delivery vehicle in this
study for the following reasons. First, Ad vectors are well
known for their ability to induce high levels of gene expres-
sion after multiple routes of administration22; second, Ad
vectors induce transient transgene expression, a quality that
is desirable in an antineoplastic therapy; and third, Ad
vectors, when administered intratumorally, induce localized
transgene expression, potentially limiting any systemic tox-
icity.22 Whether systemically administered PEDF will also
inhibit tumor growth is unknown but needs to be evaluated,
as does its potential toxicity. Despite this, the concept of
local antiangiogenesis remains an important one for the
treatment of locally advanced tumors of the chest, including
lung cancer and pulmonary metastases, as well as pleural
tumors, where local disease progression is often problem-
atic.
The Antitumor Effect of AdPEDF May Be Due to
Inhibition of Angiogenesis
The following evidence suggests that the antitumor effect of
PEDF is due to its antiangiogenesis properties. First,
AdPEDF has previously been shown to inhibit angiogenesis
in a rat corneal pocket assay8 and in murine models of
induced retinal and choroidal neovascularization.9-12 Sec-
ond, immunostaining of tumor microvasculature in the
present study demonstrated decreased microvessel density
in AdPEDF-treated tumors. Third, consistent with the anti-
neoplastic effect of antiangiogenesis agents,1-3 tumors
treated with AdPEDF did not regress and the animals were
not cured, although growth was inhibited and survival was
significantly prolonged. Whether or not other mechanisms
of tumor growth inhibition (eg, induction of tumor cell
apoptosis or tumor immunity) by AdPEDF plays a role in its
antineoplastic effect was not directly assessed in this study
but warrants further investigation. Finally, although
AdPEDF provided a survival benefit, this effect was mod-
est, implying that the tumors eventually are able to circum-
vent the antiangiogenesis induced by PEDF. As a result,
future investigation will involve strategies to “attack” the
angiogenesis process at multiple levels to make the an-
titumor effect last longer. Given the transient nature of
the antineoplastic effect of AdPEDF, such studies are
needed prior to investigating this approach in a clinical
setting.
We thank Tienne Virgin-Bryan for assistance in the preparation
of this manuscript.
Figure 7. Intrapleural administration of AdPEDF prolongs survival in a pulmonary metastasis model. One day after
intravenous administration of 3 105 CT26.CL25 tumor cells, 1010 particles of AdPEDF, AdNull, or PBS was injected
into the pleural space of BALB/c mice, and the animals followed for survival, recorded as the percentage of live
animals remaining in each group (n  7 per group).
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